Publications by authors named "Samir Undevia"

Claim this Profile
R
Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma.
Warren Chow, Paul Frankel, Chris Ruel, Dejka M Araujo, Mohammed Milhem, Samir Undevia

Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
Robin L Jones, Mark J Ratain, Peter J O'Dwyer, Lillian L Siu, Jacek Jassem, Samir Undevia

Eur J Cancer· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population.
Blase N Polite, Toni Cipriano-Steffens, Fay Hlubocky, James Dignam, Mandira Ray, Samir Undevia

J Racial Ethn Health Disparities· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.
Mark J Ratain, David Geary, Samir D Undevia, Cinthya Coronado, Vicente Alfaro

Invest New Drugs· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
Federico Innocenti, Richard L Schilsky, Jacqueline Ramírez, Linda Janisch, Samir Undevia

J Clin Oncol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.
Jacqueline Ramírez, Tae Won Kim, Wanqing Liu, Jamie L Myers, Snezana Mirkov, Samir Undevia

Pharmacogenet Genomics· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
Gary K Schwartz, William D Tap, Li-Xuan Qin, Michael B Livingston, Samir D Undevia

Lancet Oncol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
Ezra E W Cohen, Kehua Wu, Christine Hartford, Masha Kocherginsky, Kimberly Napoli Eaton, Samir D Undevia

Clin Cancer Res· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal sarcomatosis.
George I Salti, Luay Ailabouni, Samir Undevia

Ann Surg Oncol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of continuous infusion cilengitide in patients with solid tumors.
Peter H O'Donnell, Samir D Undevia, Walter M Stadler, Theodore M Karrison, M Kelly Nicholas

Invest New Drugs· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
Tara C Gangadhar, Ezra E W Cohen, Kehua Wu, Linda Janisch, David Geary, Samir D Undevia

Clin Cancer Res· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth.
Nisha C Kakodkar, Radhika Peddinti, Morris Kletzel, Yufeng Tian, Lisa J Guerrero, Samir D Undevia

Pediatr Blood Cancer· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
Peter H O'Donnell, Andrew S Artz, Samir D Undevia, Rish K Pai, Paula Del Cerro

Leuk Lymphoma· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy.
Dhara M MacDermed, Luke L Miller, Terrance D Peabody, Michael A Simon, Hue H Luu, Samir D Undevia

Int J Radiat Oncol Biol Phys· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
Michael L Maitland, Kristen E Kasza, Theodore Karrison, Kristin Moshier, Laura Sit, Samir D Undevia

Clin Cancer Res· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
Robert G Maki, David R D'Adamo, Mary L Keohan, Michael Saulle, Scott M Schuetze, Samir D Undevia

J Clin Oncol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.
Wei Peng Yong, Tae Won Kim, Samir D Undevia, Federico Innocenti, Mark J Ratain

Eur J Cancer· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
Wendy Stock, Samir D Undevia, Carol Bivins, Farhad Ravandi, Olatoyosi Odenike

Invest New Drugs· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
Samir D Undevia, Federico Innocenti, Jacqueline Ramirez, Larry House, Apurva A Desai

Eur J Cancer· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas.
Christopher W Ryan, Anthony G Montag, Janet R Hosenpud, Brian Samuels, James B Hayden, Samir Undevia

Cancer· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.
Edwin M Posadas, Samir Undevia, Elizabeth Manchen, James L Wade, A Dimitrios Colevas

Cancer Biol Ther· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spinal cord metastasis of a non-neurofibromatosis type-1 malignant peripheral nerve sheath tumor: an unusual manifestation of a rare tumor.
William S Baek, Peter Pytel, Samir D Undevia, Helene Rubeiz

J Neurooncol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic variability of anticancer agents.
Samir D Undevia, Gonzalo Gomez-Abuin, Mark J Ratain

Nat Rev Cancer· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
Samir D Undevia, Nicholas J Vogelzang, Ann M Mauer, Linda Janisch, Sridhar Mani

Invest New Drugs· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
Federico Innocenti, Samir D Undevia, Jacqueline Ramírez, Sridhar Mani, Richard L Schilsky

Clin Pharmacol Ther· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis